Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone hydrochloride for awake bruxism associated with anxiety
RBR-89z5hb7Phase 3Not yet recruiting
- Sponsor
- Universidade Federal do Paraná
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of buspirone in Awake Bruxism (AB) and generalized anxiety disorder (GAD) (3 arms), sponsored by Universidade Federal do Paraná. Primary endpoint: Frequency of awake bruxism. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
buspirone
03
Conditions
Awake Bruxism (AB)generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on RBR-89z5hb7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-89z5hb7.